FAQ: AXIM Biotechnologies' Latin America License & Distribution Agreement with JK Medical for TearScan® Ocular Diagnostic Tests

What is the main purpose of the agreement between AXIM Biotechnologies and JK Medical?

The agreement grants JK Medical exclusive rights to market and distribute AXIM’s TearScan® Lactoferrin Diagnostic Test for dry eye disease and TearScan® IgE Diagnostic Test for allergic conjunctivitis across seven Latin American countries.

Which countries are covered by this exclusive distribution agreement?

The agreement covers Brazil, Chile, Peru, Argentina, Mexico, Ecuador, and Colombia.

What specific diagnostic tests are included in this partnership?

The partnership includes the TearScan® Lactoferrin Diagnostic Test for aiding in the diagnosis of aqueous-deficient Dry Eye Disease and the TearScan® IgE Diagnostic Test for aiding in the diagnosis of allergic conjunctivitis.

When does the exclusivity period begin and how long does it last?

The 4-year exclusivity period commences once regulatory approval is obtained in 2 out of the 7 countries, with the exception of Chile where commercialization can occur immediately.

Why is this partnership significant for Latin American healthcare providers?

This partnership provides Latin American eye-care professionals with access to rapid, clinic-friendly diagnostic tools that offer objective biomarkers to complement clinical evaluation for dry eye disease and ocular allergies, addressing a significant unmet need in the region.

What roles will each company play in this collaboration?

JK Medical will lead distribution, education, and onboarding activities, while AXIM will provide product supply, training, and technical support for the TearScan® tests.

What is the unmet need in dry eye disease diagnosis that these tests address?

Current visual inspection methods cannot reliably differentiate between aqueous-deficient dry eye (inadequate tear production) and evaporative dry eye (rapid tear evaporation), nor can they identify allergic components, creating diagnostic challenges for clinicians.

How will regulatory approvals be handled across the different countries?

The companies will collaborate on country-specific registrations and compliance activities to ensure the tests meet local regulatory requirements in each of the seven Latin American markets.

What benefits do these diagnostic tests offer compared to traditional visual inspection methods?

The TearScan® tests provide objective biomarkers that complement clinical evaluation, offering more reliable differentiation between different types of dry eye disease and identifying allergic components that visual inspection alone cannot determine.